Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the foot

Florian Scotté(University of Derby), Stéphane Oudard(Délégation Paris 5), Eugéniu Banu(Hôpital Européen), Sandrine Marsan(Hôpital Européen Georges-Pompidou), Jean‐Marie Andrieu(Hôpital Européen Georges-Pompidou), Éric Levy(Hôpital Européen Georges-Pompidou), Adela Banu(Hôpital Européen), C. Ebenezer(Hôpital Européen Georges-Pompidou), Jean Marc Tourani, Jacques Médioni
Cancer
February 19, 2008
10.1002/cncr.23333
Cited by 104

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418